Drug Trial Radar · NCT05115136
Using Doxepin for Urticaria
Last checked: Nov 19, 2026Latest source record: May 18, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
160
Planned (sponsor's estimate)
Start
May 23, 2022
Primary completion
Jan 31, 2023
Study completion Jul 1, 2023
Sponsor
- Lead sponsor
- State University of New York - Upstate Medical UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 10, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, care provider)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Isolated urticaria in the emergency department is widely treated by physicians with histamine blocking agents such as diphenhydramine, cetirizine, and cimetidine. Doxepin is a tricyclic antidepressant that has been shown to have much higher concentrations of histamine blocking activity and therefore may be useful in treating urticaria. The purpose of this study is to compare the effectiveness of using doxepin verses a traditional medication, diphenhydramine (Benadryl), in the treatment of isolated urticaria in the emergency department.
Conditions
- Urticaria
Interventions
DoxepinDrug
25mg dose of Doxepin will be administered one time, by mouth
DiphenhydramineDrug
50 mg dose of Diphenhydramine will be administered one time, by mouth
Primary outcomes
What the sponsor says the trial is designed to measure.
- Improvement of urticariaTime frame: 1 hour after med administration, 2 hours after administration, and prior to discharge.
- Improvement of urticariaTime frame: 1 hour after med administration, 2 hours after administration, and prior to discharge
Locations
1 site in 1 country. Site status is shown where the registry gives one.
SUNY Upstate Medical University
Syracuse, New York · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.